Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Domain V of the poliovirus internal ribosome entry site (IRES) is a critical RNA structure that recruits host translation initiation factors to facilitate cap-independent viral protein synthesis. The primary host factors involved are the eIF4G/eIF4A complex, which binds to the lower part of Domain V, and eIF4B, which binds to the upper part. Additionally, glycyl-tRNA synthetase (GARS) and the cold shock domain-containing protein E1 (UNR/CSDE1) interact with the apical region of Domain V to stabilize the initiation complex and promote 40S ribosomal subunit recruitment. Mutations in Domain V, such as those found in the Sabin vaccine strains, impair these interactions and are major determinants of viral attenuation and neurovirulence. Targeting this interaction with small molecules or nucleic acid-based therapies represents a strategy for developing antivirals against poliovirus and related enteroviruses. Experimental inhibitors include eIF4A inhibitors like silvestrol and hippuristanol, which prevent the necessary RNA unwinding for ribosome entry, as well as antisense oligonucleotides that sterically block host factor binding sites. While effective in suppressing viral replication, therapeutic challenges include the potential for off-target effects on cellular mRNAs that utilize IRES-mediated translation and the high mutation rate of the viral genome.
Inhibition of viral translation by blocking the recruitment of the 40S ribosomal subunit or disrupting the interaction between host factors and the IRES Domain V.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host translation initiation factors interacting with poliovirus IRES domain V (eIF4G-IRES Domain V complex).